8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 3, 2009

K-V Pharmaceutical Company

(Exact name of Registrant as specified in its charter)

Delaware	1-9601	43-0618919
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

2503 South Hanley Road
St. Louis, MO	63144
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (314) 645-6600

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

     On February 3, 2009, ETHEX Corporation (“ETHEX”), a subsidiary of K-V Pharmaceutical Company (the “Company”), issued a press release announcing the commencement of a voluntary nationwide product recall of its prescription prenatal and iron supplements to the wholesale level. A copy of the press release, dated February 3, 2009, is attached hereto as Exhibit 99.1. On the same day, ETHEX issued a second press release announcing that the recall of certain products issued on January 28, 2009 is being extended from the wholesale to the retail level. A copy of the press release, dated February 3, 2009, is attached hereto as Exhibit 99.2.

     Also on February 3, 2009, Ther-Rx Corporation, also a subsidiary of the Company, issued a press release announcing the commencement of a voluntary nationwide product recall of its prescription prenatal and iron supplements to the wholesale level. A copy of the press release, dated February 3, 2009, is attached hereto as Exhibit 99.3.

     The description of the press releases set forth herein does not purport to be complete and is qualified in its entirety by reference to the full text of the press releases attached hereto as Exhibits 99.1, 99.2 and 99.3 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press Release, dated February 3, 2009, by ETHEX Corporation, announcing a voluntary nationwide product recall of its prescription prenatal and iron supplements *
99.2	Press Release, dated February 3, 2009, by ETHEX Corporation, announcing the extension of a previously issued product recall from the wholesale to the retail level *
99.3	Press Release, dated February 3, 2009, by Ther-Rx Corporation, announcing a voluntary nationwide product recall of its prescription prenatal and iron supplements *

* Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

K-V Pharmaceutical Company
By:	/s/ Robert M. Shaw
	Robert M. Shaw
	Vice President, Deputy General Counsel and Secretary

Date: February 3, 2009

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release, dated February 3, 2009, by ETHEX Corporation, announcing a voluntary nationwide product recall of its prescription prenatal and iron supplements *
99.2	Press Release, dated February 3, 2009, by ETHEX Corporation, announcing the extension of a previously issued product recall from the wholesale to the retail level *
99.3	Press Release, dated February 3, 2009, by Ther-Rx Corporation, announcing a voluntary nationwide product recall of its prescription prenatal and iron supplements *

* Filed herewith

EX-99.1

Exhibit 99.1

ETHEX Corporation Issues Voluntary Nationwide Recall of Prescription
Prenatal and Iron Supplements to Wholesale Level

February 3, 2009, St. Louis, MO — ETHEX Corporation, a subsidiary of KV Pharmaceutical Company (NYSE: KVa/KVb), is issuing a voluntary nationwide recall of the products identified below (all lots within their expiration dates) at a wholesale level. The Company is taking this action as a precautionary measure, because the products may have been manufactured under conditions that did not sufficiently comply with current Good Manufacturing Practice (cGMP).

Patients who may have these products in their possession should continue to take them in accordance with their prescriptions, as the risk of suddenly stopping needed medications may place patients at risk. Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using these products, or to obtain replacement medications or prescriptions.

Products Recalled to the Wholesale/Distributor Level:

Prescription Prenatal Vitamin Products:

Advanced NatalCare® Tablets	Advanced-RF NatalCare® Tablets
Cal-Nate™ Tablets	CareNatal™ DHA Tablets
ComBgen Tablets	ComBiRx™Tablets
NataCaps Capsules	NatalCare Gloss Tablets
NatalCare PIC Tablets	NatalCare PIC Forte Tablets
NatalCare Plus Tablets	NatalCare Rx Tablets
NatalCare Three Tablets	NataTab FA Tablets
NataTab RX Tablets	NutriNate® Chewable Tablets
NutriSpire™ Tablets	Prenatal MR 90 FE Tablets
Prenatal MTR w/Selinium Tablets	Prenatal Rx 1 Tablets
Prenatal Z, Advanced Formula Tablets	Ultra NatalCare Tablets

Prescription Iron Supplement Products:

Anemagen Caplets	Anemagen Forte Caplets
Conison™ Capsules	Fe-Tinic™ 150 Forte Capsules

Any wholesaler inquiries related to this action should be addressed to ETHEX Customer Service at 1-800-748-1472, faxed to ETHEX Customer Service at 314-646-3788, or e-mailed to customer-service@ethex.com. Representatives are available Monday through Friday, 8 am to 5 pm CST.

ETHEX Corporation has initiated recall notifications to wholesalers nationwide who received any inventory of the recalled products, with instructions for returning the recalled products.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration (FDA). At this time, the Company is unable to determine when distribution of these products will resume.

Patients with questions about the recall should call the telephone number above, or contact their healthcare providers. Any adverse reactions experienced with the use of these products should also be reported to FDA’s MedWatch Program by phone at 1-800-FDA-1088, by fax at 1-800-FDA-0178, by mail at MedWatch, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch website at www.fda.gov/medwatch.

The recall announcement is posted on www.kvpharmaceutical.com.

About KV Pharmaceutical Company

KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures, markets, and acquires technology-distinguished branded and generic/non-branded prescription pharmaceutical products. The Company markets its technology distinguished products through ETHEX Corporation, a national leader in generic pharmaceuticals, and Ther-Rx Corporation, its branded drug subsidiary.

EX-99.2

Exhibit 99.2

ETHEX Corporation Issues Voluntary Nationwide Recall

Previously Issued Recall to Wholesale Level on
Certain Products Expanded to Retail Level

February 3, 2009, St. Louis, MO — ETHEX Corporation, a subsidiary of KV Pharmaceutical Company (NYSE: KVa; KVb), is issuing a voluntary expansion to the retail level of a previously announced recall on certain products. The recall on the products listed below had previously been issued to the wholesale level, but is now being expanded to the retail level. The Company is taking this action as a precautionary measure, because the products may have been manufactured under conditions that did not sufficiently comply with current Good Manufacturing Practice (cGMP). This additional level of recall is to further remove recalled products from the marketplace.

Patients who may have these products in their possession should continue to take them in accordance with their prescriptions, as the risk of suddenly stopping needed medications may place patients at risk. Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using these products.

Expanded Recall to Retail Level Includes the Following Products:

Morphine Sulfate Extended-Release Tablets 15mg, 30mg & 60mg (All Strengths)
Morphine Sulfate Immediate-Release Tablets 15mg & 30 mg (All Strengths)
Dextroamphetamine Sulfate Tablets 5mg & 10mg (All Strengths)
Isosorbide Mononitrate Extended-Release Tablets 30mg, 60mg & 120mg (All Strengths)
Propafenone HCl Tablets 150mg, 225mg & 300 mg (All Strengths)

Any retail customer inquiries related to this action should be addressed to ETHEX Customer Service at 1-800-748-1472, faxed to ETHEX Customer Service at 314-646-3788, or e-mailed to customer-service@ethex.com. Representatives are available Monday through Friday, 8 am to 5 pm CST.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration (FDA). At this time, the Company is unable to determine when distribution of these products will resume.

Patients with questions about the recall should call the telephone number above, or contact their healthcare providers. Any adverse reactions experienced with the use of these products should also be reported to FDA’s MedWatch Program by phone at 1-800-FDA-1088, by fax at 1-800- FDA-0178, by mail at MedWatch, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch website at www.fda.gov/medwatch

The recall announcement is posted on www.kvpharmaceutical.com.

About KV Pharmaceutical Company

KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures, markets, and acquires technology-distinguished branded and generic/non-branded prescription pharmaceutical products. The Company markets its technology distinguished products through ETHEX Corporation, a nationwide leader in generic pharmaceuticals and Ther-Rx Corporation, its branded drug subsidiary.

EX-99.3

Exhibit 99.3

Ther-Rx Corporation Issues Voluntary Nationwide Recall of Prescription
Prenatal and Iron Supplements to Wholesale Level

February 3, 2009, St. Louis, MO — Ther-Rx Corporation, a subsidiary of KV Pharmaceutical Company (NYSE: KVa/KVb), is issuing a voluntary nationwide recall of prescription prenatal and iron supplement nutritionals as identified below (all lots within their expiration dates) at a wholesale level. The Company is taking this action as a precautionary measure, because the products may have been manufactured under conditions that did not sufficiently comply with current Good Manufacturing Practice (cGMP).

Patients who may have these products in their possession should continue to take them in accordance with their prescriptions, as the risk of suddenly stopping needed medication may place patients at risk. Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using these products, or to obtain replacement medications or prescriptions.

Products Recalled to the Wholesale Level:

Prescription Iron Supplement Products:

Chromagen® Caplet	Chromagen® FA Caplet
Chromagen® Forte Caplet	Encora® Capsule
Niferex® Gold Tablet	Niferex® 150 Forte Capsule
Repliva 21/7® Tablet

Prescription Prenatal Vitamin Products:

PreCare® Chewable Tablet	PreCare® Conceive Tablet
PreCare Premier® Tablet	PremesisRx® Tablet
PrimaCare® Capsule/Tablet	PrimaCare® Advantage™ Capsule/Tablet
PrimaCare® ONE Capsule

Any retail customer inquiries related to this action should be addressed to Ther-Rx Customer Service at 877-567-7676, or faxed to Ther-Rx Customer Service at (314) 646-3701, or e-mailed to info@ther-rx.com. Representatives are available Monday through Friday, 8 am to 5 pm CST.

Ther-Rx Corporation has initiated recall notifications to wholesalers nationwide who received any inventory of the recalled products, with instructions for returning the recalled products. Patients with questions about the recall should call the telephone number above, or contact their healthcare providers.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration (FDA). At this time, the Company is unable to determine when distribution of these products will resume.

Any adverse reactions experienced with the use of these products should also be reported to the FDA’s MedWatch Program by phone at 1-800-FDA-1088, by fax at 1-800-FDA-0178, by mail at MedWatch, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch website at www.fda.gov/medwatch.

The recall announcement is posted on www.kvpharmaceutical.com.

About KV Pharmaceutical Company

KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures, markets, and acquires technology-distinguished branded and generic/non-branded prescription pharmaceutical products. The Company markets its technology distinguished products through ETHEX Corporation, a national leader in generic pharmaceuticals, and Ther-Rx Corporation, its branded drug subsidiary.